AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action

Aardvark Therapeutics faces a pending securities class action alleging it overstated the safety and prospects of ARD-101, its Phase 3 Prader-Willi syndrome candidate. The company voluntarily paused its Phase 3 HERO trial on February 27, 2026 after reversible cardiac observations at above-target doses, triggering a share-price decline of more than 56%; the FDA subsequently imposed a full clinical hold on May 14, halting all ARD-101 studies and driving a further 32.1% drop. Investors have until October 13, 2026 to seek appointment as lead plaintiff.

Analysis

This is not a new fundamental catalyst; plaintiff-firm notices typically add negligible incremental valuation information after a clinical hold and trial interruption have already reset the asset’s probability of approval. The relevant underwriting question is FDA remediation: if the cardiac signal is dose-dependent and reversible, value may persist through a lower-dose protocol, but a narrow therapeutic window would materially impair efficacy, trial design, and eventual label economics. With no diversified revenue base, AARD is effectively a long-duration binary on the agency’s required nonclinical/clinical package and its ability to restart enrollment.

Near term (days to the October 13 lead-plaintiff deadline), litigation headlines could worsen liquidity and deter marginal buyers, but litigation itself is unlikely to be the principal driver. Over 1-3 months, management disclosure on the FDA hold letter, root-cause analysis, dose-response findings, cash runway, and expected resubmission timing will determine whether the equity retains option value or requires dilutive financing. A prolonged hold also gives alternative PWS-management approaches and future hyperphagia entrants additional time to establish physician, caregiver, and advocacy-network positioning.

Contrarianly, the stock’s post-hold impairment may already discount a substantial probability of permanent discontinuation; a clearly bounded electrophysiology issue and FDA-agreed restart path could produce a sharp reflexive recovery from a depressed base. That is not yet investable without visibility into exposure-adjusted safety margins and remaining cash. The bearish thesis is falsified by a disclosed restart agreement with no meaningful dose reduction and a runway sufficient to reach a definitive efficacy readout; it is reinforced by additional cardiac events at target exposure, a mandated large safety study, or financing before restart.

Key Decisions for Investors

• No new directional position solely on this lawsuit notice; treat it as a liquidity/volatility alert rather than an independent short catalyst.
• Maintain or initiate a small tactical AARD short only on a liquidity-driven bounce ahead of substantive FDA-hold disclosure, with a 1-3 month horizon; cover on an FDA-agreed restart announcement or if shares rise more than 25% above entry absent new financing or safety data.
• For event-driven portfolios, monitor FDA correspondence, protocol amendments, cardiac-monitoring data, and quarterly cash burn. Consider a defined-risk long only after an announced restart path, using call spreads rather than common equity until dose and efficacy implications are known.
• Set a financing watch: if projected cash runway does not extend through a restarted pivotal trial, expect dilution to become the dominant valuation driver; avoid unhedged longs until the capital plan is disclosed.